Evidence map›Paper›PMID 26293670›Full record

ReviewEpilepsia2015

Should epileptiform discharges be treated?

Iván Sánchez Fernández, Tobias Loddenkemper, Aristea S Galanopoulou, Solomon L Moshé

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Epilepsia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04141332 (Specific Language Impairment), which is not on this map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04141332 completednot on this mapstarted 2018, after this paper: background citation

Specific Language Impairment (SLI) in Children May Caused by Epileptic Brain Activity

TypeobservationalSponsorMansoura University HospitalRan2018 to 2019Enrolled160ConditionsSpecific Language ImpairmentArmsEEG was recorded by EEG Machines
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 70 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. The role of SLC transporters for brain health and disease.Cellular and molecular life sciences : CMLS · 2021
    Review
  11. Article
  12. Article
  13. Cycles in epilepsy.Nature reviews. Neurology · 2021
    Review
  14. Review
  15. Review
  16. Article
  17. Epilepsy in Children with Autistic Spectrum Disorder.Children (Basel, Switzerland) · 2019
    Article
  18. Article
  19. Language Dysfunction in Pediatric Epilepsy.The Journal of pediatrics · 2018
    Review
  20. Transient Cognitive Impairment in Epilepsy.Frontiers in molecular neuroscience · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Iván Sánchez FernándezDivision of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, U.S.A.
Tobias LoddenkemperDepartment of Child Neurology, Hospital Sant Joan de Déu, University of Barcelona, Spain.
Aristea S GalanopoulouSaul R. Korey Department of Neurology, Dominick P. Purpura Department of Neuroscience, Laboratory of Developmental Medicine, Montefiore/Einstein Epilepsy Management Center, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Solomon L MoshéSaul R. Korey Department of Neurology, Dominick P. Purpura Department of Neuroscience, Laboratory of Developmental Medicine, Montefiore/Einstein Epilepsy Management Center, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Hospital Sant Joan de Déu Barcelona · ESMontefiore Medical Center · US

Funding

Impact of Initial Therapy and Response on Long Term Outcome in Children with CAEU01NS045911 · NINDS · CINCINNATI CHILDRENS HOSP MED CTR · PI GLAUSER, TRACY A · 2003 to 2013
$31.1M
Consequences of Prolonged Febrile Seizures in ChildhoodR01NS043209 · NINDS · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI SHINNAR, SHLOMO · 2003 to 2012
$21.5M
Consequences of Prolonged Febrile Seizures in ChildhoodR37NS043209 · NINDS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI SHINNAR, SHLOMO · 2013 to 2019
$11.4M
AGE RELATED SEIZURE SUPPRESSIONR01NS020253 · NINDS · YESHIVA UNIVERSITY · PI MOSHE, SOLOMON L. · 1985 to 2011
$4.7M
Age related seizure suppressionR56NS020253 · NINDS · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI MOSHE, SOLOMON L. · 2007 to 2007
$498k
Screening for new therapies for refractory infantile spasmsR21NS078333 · NINDS · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI GALANOPOULOU, ARISTEA S · 2012 to 2013
$452k
NINDS NIH HHS NS20253NINDS NIH HHS NS43209NINDS NIH HHS NS45911NINDS NIH HHS NS-78333NINDS NIH HHS R01 NS020253NINDS NIH HHS R01 NS043209NINDS NIH HHS R21 NS078333NINDS NIH HHS R37 NS043209NINDS NIH HHS R56 NS020253NINDS NIH HHS U01 NS045911
6 · The paper itself

Abstract

To evaluate the impact of epileptiform discharges (EDs) that do not occur within seizure patterns--such as spikes, sharp waves or spike waves--on cognitive function and to discuss the circumstances under which treatment of EDs might be considered. Methods used in this article is "Review of the literature". EDs may disrupt short-term cognition in humans. Frequent EDs for a prolonged period can potentially impair long-term cognitive function in humans. However, there is conflicting evidence on the impact of EDs on long-term cognitive outcome because this relationship may be confounded by multiple factors such as underlying etiology, seizures, and medication effects. Limitations of existing studies include the lack of standardized ED quantification methods and of widely accepted automated spike quantification methods. Although there is no solid evidence for or against treatment of EDs, a non-evidence-based practical approach is suggested. EDs in otherwise asymptomatic individuals should not be treated because the risks of treatment probably outweigh its dubious benefits. A treatment trial for EDs may be considered when there is cognitive dysfunction or regression or neurologic symptoms that are unexplained by the underlying etiology, comorbid conditions, or seizure severity. In patients with cognitive or neurologic dysfunction with epilepsy or EDs, treatment may be warranted to control the underlying epileptic syndrome. EDs may cause cognitive or neurologic dysfunction in humans in the short term. There is conflicting evidence on the impact of EDs on long-term cognitive outcome. There is no evidence for or against treatment of asymptomatic ED.

Indexed as

Autism Spectrum DisorderBrain WavesCognition DisordersEpilepsyFunctional LateralityHumansIntellectual DisabilityLanguage DisordersNeuropsychological TestsAntiepileptic drugsCognitionEpileptiform dischargesMemorySleep

Identifiers

PMID26293670
PMCPMC6294573
OpenAlexW2157867380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.